The chameleon of neuroinflammation: Magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

Multiple Sclerosis Journal

Volumn 19, Issue 14, 2013, Pages 1826-1840

  Wattjes, Mike P ^a   Richert, Nancy D ^b   Killestein, Joep ^a   De Vos, Marlieke ^a   Sanchez, Esther ^a   Snaebjornsson, Petur ^a   Cadavid, Diego ^b   Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BIOGEN   (United States)

Author keywords

magnetic resonance imaging; Multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Indexed keywords

GADOLINIUM; NATALIZUMAB;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; CEREBRAL BLINDNESS; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; ELECTRON MICROSCOPY; EXPANDED DISABILITY STATUS SCALE; GRAY MATTER; HISTOPATHOLOGY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; POSTERIOR FOSSA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SEIZURE; SURVIVAL RATE; WHITE MATTER LESION;

MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NATALIZUMAB; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; DEMYELINATING DISEASES; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGIC FACTORS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; PREDICTIVE VALUE OF TESTS;

EID: 84888627559     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513510224     Document Type: Review

References (72)

1. Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy. Brain. 1958 ; 81: 93-127
2. Padget BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971 ; 1: 1257-1260
3. Frisque RJ, Bream GL, Canella MT. Human polyomavirus JC virus genome. J Virol. 1984 ; 51: 458-469
4. Cinque P, Koralnik IJ, Gerevini S, et al. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis. 2009 ; 9: 625-636
5. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol. 2010 ; 9: 438-446
6. Sha R, Bag AK, Chapman PR, et al. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol. 2010 ; 65: 431-439
7. Rudick R, Polman C, Clifford D, et al. Natalizumab: Bench to bedside and beyond. JAMA Neurol. 2013 ; 70: 172-182
8. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 ; 354: 924-933
9. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring. Lancet Neurol. 2011 ; 10: 745-758
10. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leuko-encephalopathy. N Engl J Med. 2012 ; 366: 1870-1880
11. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012 ; 18: 143-152
12. Biogen Idec medical information, https://medinfo.biogenidec.com September 2012. Accessed 2013.
13. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol. 2010 ; 9: 425-437
14. Brew BJ, Davies NW, Cinque P, et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010 ; 6: 667-679
15. Takeda S, Yamazaki K, Miyakawa T, et al. Progressive multifocal leukoencephalopathy showing extensive spinal cord involvement in a patient with lymphocytopenia. Neuropathology. 2009 ; 29: 485-493
16. Bernal-Cano F, Joseph JT, Koralnik IJ. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol. 2007 ; 13: 474-476
17. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?. Ann Neurol. 2006 ; 60: 162-173
18. Gheuens S, Wüthrich C, Koralnik IJ. Progressive multifocal leukoencephalopathy: Why gray and white matter. Annu Rev Pathol. 2013 ; 8: 189-215
19. Wüthrich C, Koralnik IJ. Frequent infection of cortical neurons in JC virus patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 2012 ; 71: 54-65
20. Du Pasquier RA, Corey S, Margolin DH. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology. 2003 ; 61: 775-782
21. Koralnik IJ, Wüthrich C, Dang X, et al. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol. 2005 ; 57: 576-580
22. Wütrich C, Dang X, Westmoreland S, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol. 2009 ; 65: 742-748
23. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013 ; 80: 1430-1438
24. Mentzer D, Prestel J, Adams O, et al. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry. 2012 ; 83: 927-933
25. Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology. 2006 ; 66: 262-264
26. Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011 ; 77: 1061-1067
27. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009 ; 361: 1081-1087
28. Ryschkewitsch CF, Jensen PN, Monaco MC, et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2010 ; 68: 384-391
29. Kuhle J, Gosert R, Bühler R, et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology. 2011 ; 77: 2010-2016
30. Berger JR, Clifford DB. The manifold faces of PML and the challenge of diagnosis. Neurology. 2011 ; 77: 2006-2007
31. Eisele P, Szabo K, Griebe M, et al. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy. J Neuroimaging. :
32. Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology. 2012 ; 78: 507-508
33. Yousry TA, Pelletier D, Cadavid D, et al. MRI pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 ; 72: 779-787
34. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry. 2012 ; 83: 224-226
35. Phan-Ba R, Belachew S, Outteryck O, et al. The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas?. Neurology. 2012 ; 79: 1067-1069
36. Blinkenberg M, Sellebjerg F, Leffers AM, et al. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. Mult Scler. 2013 ; 19: 1226-1229
37. Lindå H, von Heijne A. Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol. 2013 ; 4: 11
38. Dong-Si T, Richman S, Bloomgren G, et al. Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients: Survival and functional outcome when asymptomatic at diagnosis. Presented at the 65th Meeting of the American Academy of Neurology ; San Diego, CA ;..
39. Richert N, Bloomgren G, Cadavid D, et al. Imaging findings for PML in natalizumab-treated MS patients. Mult Scler. 2012 ; 18 27: P99
40. Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal leukoencephalopathy: Diffusion-weighted imaging and pathological correlations. Neuroradiology. 2004 ; 46: 22-25
41. Vennegoor A, Wattjes MP, van Munster ET, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 2011 ; 76: 574-576
42. Seewann A, Vrenken H, van der Valk P, et al. Diffusely abnormal white matter in chronic multiple sclerosis: Imaging and histopathologic analysis. Arch Neurol. 2009 ; 66: 601-609
43. Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: Similarities and differences. Neurology. 2008 ; 70: 336-343
44. Tyler KL. The uninvited guest: JC virus infection of neurons in PML. Neurology. 2003 ; 61: 734-735
45. Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology. 2012 ; 78: 302-308
46. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, et al. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012 ; 71: 604-617
47. Sweeney BJ, Manji H, Miller RF, et al. Cortical and subcortical JC virus infection: Two unusual cases of AIDS associated progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 1994 ; 57: 994-997
48. Bienfait HP, Louwerse ES, Portegies P, et al. Progressive multifocal leukoencephalopathy presenting as a solitary gray matter lesion. J Neurol. 1998 ; 245: 557-558
49. Wattjes MP, Verhoeff L, Zentjens W, et al. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: Productive JC virus infection or preclinical PML-IRIS manifestation?. J Neurol Neurosurg Psychiatry. 2013 ; 84: 1176-1177
50. Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 2012 ; 78: 1390-1393
51. Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management. Neurology. 2012 ; 79: 2258-2264
52. Berger JR. Steroids for PML-IRIS: A double-edged sword?. Neurology. 2009 ; 72: 1454-1455
53. Boster AL, Nicholas JA, Topalli I, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013 ; 70: 398-402
54. Post MJ, Thurnher MM, Clifford DB, et al. CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: Overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome. AJNR Am J Neuroradiol. 2013 ; 34: 1297-1307
55. Post MJ, Thurnher MM, Clifford DB, et al. CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 2: Discussion of neuro-immune reconstitution inflammatory syndrome with and without other pathogens. AJNR Am J Neuroradiol. 2013 ; 34: 1308-1318
56. Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and meta-analysis. Lancet Infect Dis. 2010 ; 10: 251-261
57. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011 ; 76: 1697-1704
58. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol. 2012 ; 123: 235-245
59. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009 ; 361: 1075-1080
60. Karnofsky DA, Burchenal JH Evaluation of chemotherapeutic agents. MacLeod CM, ed. New York: Columbia University Press ; 1949: 196.
61. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
62. Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2012 ; 19: 593-600
63. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403
64. Cañellas AR, Gols AR, Izquierdo JR, et al. Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology. 2007 ; 49: 393-409
65. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol. 1998 ; 19: 675-683
66. Boster A, Hreha S, Berger JR, et al. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: A comparative study. Arch Neurol. 2009 ; 66: 593-599
67. Wattjes MP, Barkhof F. High field MRI in the diagnosis of multiple sclerosis: High field-high yield?. Neuroradiology. 2009 ; 51: 279-292
68. Kilsdonk ID, de Graaf WL, Barkhof F, et al. Inflammation high-field magnetic resonance imaging. Neuroimaging Clin N Am. 2012 ; 22: 135-157
69. Seewann A, Enzinger C, Filippi M, et al. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: A review of reported findings. J Neurol. 2008 ; 255: 1-10
70. Visser F, Wattjes MP, Pouwels PJ, et al. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology. 2012 ; 79: 2000-2003
71. Rossi A. Imaging of acute disseminated encephalomyelitis. Neuroimaging Clin N Am. 2008 ; 18: 149-161
72. Décard BF, Haghikia A, Tönnes C, et al. Natalizumab- associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Mult Scler. 2013 ; 19: 249-251